Vivos Therapeutics, Inc. - Common Stock (VVOS)
4.4200
+0.5900 (15.40%)
NASDAQ · Last Trade: Jul 3rd, 1:02 PM EDT
Detailed Quote
| Previous Close | 3.830 |
|---|---|
| Open | 3.890 |
| Bid | 4.420 |
| Ask | 4.430 |
| Day's Range | 3.875 - 4.500 |
| 52 Week Range | 1.970 - 6.280 |
| Volume | 901,553 |
| Market Cap | 26.03M |
| PE Ratio (TTM) | -2.555 |
| EPS (TTM) | -1.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,550,328 |
Chart
About Vivos Therapeutics, Inc. - Common Stock (VVOS)
Vivos Therapeutics Inc is a medical technology company focused on developing and commercializing innovative solutions for the treatment of obstructive sleep apnea and other sleep-related disorders. The company specializes in non-invasive therapies, including uniquely designed oral appliances that aim to improve airway patency during sleep. Vivos Therapeutics collaborates with dental practitioners and healthcare professionals to provide comprehensive care options for patients, enhancing both their sleep quality and overall health. Through its research and development efforts, the company seeks to advance the understanding of sleep disorders and create effective therapies that address the underlying causes of these conditions. Read More
News & Press Releases
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · July 2, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · July 1, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · July 1, 2025
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering.
Via Benzinga · September 19, 2024
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · June 26, 2025
Via Benzinga · June 20, 2025
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind”
December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind.” The report can be accessed here.
Via TheNewswire.com · December 10, 2024
Via Benzinga · December 2, 2024
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (“OSA”) in adults and children, reported that the American Medical Association (“AMA”) has issued new CPT(R)medical codes that are applicable to Vivos CARE oral medical devices; the codes are effective beginning Jan. 1, 2025.
Via Investor Brand Network · October 8, 2024
Via Benzinga · September 19, 2024
Via Benzinga · September 19, 2024
NVDA, TMUS, VVOS, SOFI, TSLA are the top trending stocks on Wednesday.
Via Benzinga · September 18, 2024
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), has entered into definitive purchase agreements with institutional investors. Under these agreements, Vivos will issue and sell an aggregate of 1,363,812 shares of its common stock at a purchase price of $3.15 per unit in a registered direct offering.
Via Investor Brand Network · September 19, 2024
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17.
Via Benzinga · September 18, 2024
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (“SRBDs”) including obstructive sleep apnea (“OSA”) has received breakthrough clearance from the U.S. Food and Drug Administration (“FDA”). According to the announcement, the company has received approval to use its Vivos proprietary oral medical device to treat moderate to severe OSA and snoring in children; the company believes this is the first time the FDA has given 510(k) clearance for this type of treatment for children aged 6 to 17 years of age.
Via Investor Brand Network · September 18, 2024
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting the financial results and operating highlights for its second quarter 2024 and six-month period, which ended June 30, 2024. Highlights of the report include a 19% increase in revenue both sequentially and year-over-year; a 31% decrease in operating expenses, marking eight consecutive quarters of improvement based on successful cost-cutting initiatives; and $6.9 million in cash and cash equivalents with stockholder equity totaling $6.3 million.
Via Investor Brand Network · August 15, 2024
VVOS stock results show that Vivos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024. In addition, the company’s management will host a conference at 5 p.m. ET to review the results and provide an overview of Vivos’ recent achievements and developments. Interested participants can dial (800) 717-1738 (local) or (646) 307-1865 (international) and use the passcode 1157721. A live webcast of the call can be accessed on the company’s website.
Via Investor Brand Network · August 14, 2024
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting on the positive results from seven-month pilot test. The multisite marketing initiative tested the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model. Earlier this month, the company unveiled the new marketing and distribution model designed to drive revenue through collaborations with dentists and sleep-treatment providers. The pilot, which involved seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles, provided a way to offer obstructive sleep apnea (“OSA”) patients a range of evidence-based treatments for OSA. Included in the treatment options were Vivos’ advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. According to the announcement, results indicated that 79% (60 out of 76) newly diagnosed adult OSA patients chose Vivos’ oral appliance therapy over either continuous positive airway pressure (“CPAP”) machines or doing nothing. The report also indicated that 5% (4 out of 76) of patients declined all treatment options with 16% (12 out of 76) patients chosing to investigate CPAP as an option before making a final decision. “We are excited about the positive results of this pilot program and what the data shows about the potential for our new marketing and distribution model,” said Vivos Therapeutics chair and CEO Kirk Huntsman in the press release. “The message is clear: when Vivos teams up with medical professionals who treat OSA, and when patients are fully informed as to the health risks of untreated OSA and the full range of treatment options available in an open and transparent manner, they overwhelmingly chose Vivos’ CARE oral medical devices. As we continue to expand beyond dentists and move more directly and vertically into affiliations and collaborations with medical specialists, functional medicine doctors, and other sleep-related healthcare practitioners, we expect this to positively impact our new case starts, revenue growth and gross profit.”
Via Investor Brand Network · June 27, 2024